Forrester L, Ballentine R, Dana W J
Contemp Pharm Pract. 1980 Summer;3(3):134-40.
During 1977, M.D. Anderson Hospital and Tumor Institute used 270,575 g of human serum albumin (HSA) at a patient cost of $1.1 million. For a 1-month period in early 1978, a survey of HSA usage was conducted in the 440-bed hospital. Patients who were started on albumin during the study period were included and monitored for the duration of their therapy. The largest groups of patients receiving albumin were those with gynecological tumors (30%) and gastrointestinal tumors (16%). Two-thirds of all patients receiving HSA were also receiving intravenous hyperalimentation (IVH); 80% of all HSA used was given to IVH patients. Although the IVH patients received a smaller daily dose of HSA, the average length of their therapy was about three times longer than that of the non-IVH patients. The mean total dose for the IVH patients was 344 g as compared to 180 g for non-IVH patients. For all patients, the mean total dose of HSA was 289 g at a patient cost of $1212. Of the patients, 66% had an initial serum albumin level determined before therapy was begun, 43% had a serum albumin level run at the termination of therapy, 16% had neither, and 28% had only one serum albumin level during their HSA therapy. Ninety percent of the patients had at least one period of 4 days or longer without a serum albumin level being obtained.
1977年期间，安德森肿瘤医院使用了270,575克人血清白蛋白（HSA），患者费用为110万美元。1978年初的一个月时间里，对这家拥有440张床位的医院的HSA使用情况进行了调查。研究期间开始使用白蛋白的患者被纳入并在整个治疗期间进行监测。接受白蛋白治疗的患者中，人数最多的群体是患有妇科肿瘤的患者（30%）和胃肠道肿瘤患者（16%）。所有接受HSA治疗的患者中有三分之二同时也在接受静脉高营养治疗（IVH）；所有使用的HSA中有80%给予了接受IVH治疗的患者。尽管接受IVH治疗的患者每日使用的HSA剂量较小，但其平均治疗时长约是非IVH治疗患者的三倍。接受IVH治疗的患者的平均总剂量为344克，而非IVH治疗患者为180克。所有患者的HSA平均总剂量为289克，患者费用为1212美元。在这些患者中，66%在治疗开始前测定了初始血清白蛋白水平，43%在治疗结束时进行了血清白蛋白水平检测，16%两者都没有检测，28%在接受HSA治疗期间只检测了一次血清白蛋白水平。90%的患者至少有一个为期4天或更长时间未进行血清白蛋白水平检测的阶段。
